These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12870767)

  • 1. The role of gastric acid in preventing foodborne disease and how bacteria overcome acid conditions.
    Smith JL
    J Food Prot; 2003 Jul; 66(7):1292-303. PubMed ID: 12870767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of acid secretion in peptic ulcer disease.
    Feldman M
    J Clin Gastroenterol; 1995; 20 Suppl 1():S1-6. PubMed ID: 7673607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate reduction of gastric acid secretion in the treatment of peptic ulcer disease.
    Jaup BH
    Scand J Gastroenterol Suppl; 1985; 111():36-40. PubMed ID: 2861651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.
    Sanduleanu S; Jonkers D; De Bruïne A; Hameeteman W; Stockbrügger RW
    Aliment Pharmacol Ther; 2001 Aug; 15(8):1163-75. PubMed ID: 11472319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptic ulcer pathophysiology.
    Mertz HR; Walsh JH
    Med Clin North Am; 1991 Jul; 75(4):799-814. PubMed ID: 2072787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study.
    Hurenkamp GJ; Grundmeijer HG; Van Der Ende A; Tytgat GN; Assendelft WJ; Van Der Hulst RW
    Aliment Pharmacol Ther; 2001 Jul; 15(7):1047-54. PubMed ID: 11421881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid suppression and the gastric flora.
    Heatley RV; Sobala GM
    Baillieres Clin Gastroenterol; 1993 Mar; 7(1):167-81. PubMed ID: 8477111
    [No Abstract]   [Full Text] [Related]  

  • 9. Is smoking still important in the pathogenesis of peptic ulcer disease?
    Eastwood GL
    J Clin Gastroenterol; 1997; 25 Suppl 1():S1-7. PubMed ID: 9479620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy with antacids].
    Holtermüller KH
    Fortschr Med; 1979 Jun; 97(23):1068-71, 1087. PubMed ID: 37146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the use of gastric acid-inhibitory drugs--physiological and pathophysiological considerations.
    Waldum HL; Brenna E; Kleveland PM; Sandvik AK; Syversen U
    Aliment Pharmacol Ther; 1993 Dec; 7(6):589-96. PubMed ID: 7909240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion.
    Rune S
    Digestion; 1992; 51 Suppl 1():11-6. PubMed ID: 1397740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer.
    Kuipers EJ
    Aliment Pharmacol Ther; 1997 Apr; 11 Suppl 1():71-88. PubMed ID: 9146793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids.
    Bonten MJ; Gaillard CA; van der Geest S; van Tiel FH; Beysens AJ; Smeets HG; Stobberingh EE
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1825-34. PubMed ID: 8520743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimal use of acid-inhibitors in acid-related diseases. Physiological and physiopathological considerations with implications on therapeutic choice].
    Waldum HL
    Tidsskr Nor Laegeforen; 1993 Feb; 113(4):465-9. PubMed ID: 8465291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities.
    Ishikawa H; Ito H; Higaki M; Higaki M; Matsumoto Y; Kamimura T; Katsura Y; Tomishi T; Inoue Y; Takasugi H; Tomoi M; Krakowka S; Yoshida K
    Eur J Pharmacol; 1999 Aug; 378(3):299-310. PubMed ID: 10493106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptic ulcer disease: physiology and pathophysiology.
    Holt KM; Isenberg JI
    Hosp Pract (Off Ed); 1985 Jan; 20(1):89-93, 96-101, 104-6. PubMed ID: 2856923
    [No Abstract]   [Full Text] [Related]  

  • 18. Antacids and peptic ulcer--a reappraisal.
    Morris T; Rhodes J
    Gut; 1979 Jun; 20(6):538-45. PubMed ID: 38192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.
    Konturek SJ; Konturek PC; Konturek JW; Plonka M; Czesnikiewicz-Guzik M; Brzozowski T; Bielanski W
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():29-50. PubMed ID: 17033104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease.
    Smolka AJ; Schubert ML
    Curr Top Microbiol Immunol; 2017; 400():227-252. PubMed ID: 28124156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.